Proteasome inhibition induces hepatic stellate cell apoptosis

Area of Science:

• Hepatology
• Cell Biology
• Pharmacology

Background:

• Hepatic fibrosis is a significant health concern, and inducing apoptosis in hepatic stellate cells (HSCs) is a promising therapeutic strategy.
• Nuclear factor kappa B (NF-kappaB) activation is crucial for HSC survival and proliferation.
• Understanding mechanisms to induce HSC apoptosis is critical for developing effective anti-fibrotic therapies.

Purpose of the Study:

• To investigate the efficacy of proteasome inhibitors in inducing apoptosis of hepatic stellate cells (HSCs).
• To elucidate the role of NF-kappaB signaling in proteasome inhibitor-induced HSC apoptosis.
• To evaluate the therapeutic potential of proteasome inhibition in a mouse model of liver fibrosis.

Main Methods:

• Treatment of immortalized human HSCs (LX-2) and primary rat HSCs with proteasome inhibitors bortezomib and MG132.
• Assessment of HSC apoptosis, NF-kappaB activation, and expression of key target genes.
• In vivo validation using a bile-duct-ligated mouse model of liver fibrosis.

Main Results:

• Both bortezomib and MG132 effectively induced apoptosis in HSCs.
• Proteasome inhibition suppressed NF-kappaB activation, and direct NF-kappaB inhibition also triggered HSC apoptosis.
• Knockdown of the NF-kappaB target gene A1 induced HSC apoptosis, indicating its anti-apoptotic role in HSC survival.
• Bortezomib treatment reduced markers of HSC activation and fibrosis in vivo.

Conclusions:

• Proteasome inhibitors are potent inducers of HSC apoptosis.
• The NF-kappaB signaling pathway, particularly the A1 gene, plays a critical role in HSC survival.
• Proteasome inhibition represents a viable therapeutic strategy for treating liver fibrosis by targeting HSCs.